Two cases of therapy-refractory chilblain lupus erythematosus successfully treated with deucravacitinib
Lupus · 2026
DOI: 10.1177/09612033261473986 ↗Kurz gefasst
Fallbericht in der Zeitschrift Lupus, 2026. Verfasst von Robin Springer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Duesseldorf, Duesseldorf, Germany. Hauptthemen laut MEDLINE: Lupus Erythematosus, Cutaneous, Chilblains, TYK2 Kinase. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Chilblain lupus erythematosus is a rare skin manifestation of lupus erythematosus (LE), which has proven particularly difficult to treat and therefore often presents a great challenge for patients and physicians. We treated two patients with cases of long-lasting, refractory chilblain LE with the selective, allosteric TYK2-inhibitor deucravacitinib. Both patients showed rapid improvement of their respective skin lesions and symptoms. The treatment was generally well tolerated with no severe adverse events. One of the patients experienced an intermittent occurrence of acne lesions. We therefore suggest deucravacitinib as a promising and safe off-label treatment option for chilblain LE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University Hospital Duesseldorf, Duesseldorf, Germany.
ORCID-Profile: Robin Springer
Zitieren
APA
Springer, R., Moufarrej, A., Homey, B., & Meller, S. (2026). Two cases of therapy-refractory chilblain lupus erythematosus successfully treated with deucravacitinib. Lupus. https://doi.org/10.1177/09612033261473986
Vancouver
Springer R, Moufarrej A, Homey B, Meller S. Two cases of therapy-refractory chilblain lupus erythematosus successfully treated with deucravacitinib. Lupus. 2026. doi:10.1177/09612033261473986
BibTeX
@article{Springer2026,
author = {Springer, Robin and Moufarrej, Andrew and Homey, Bernhard and Meller, Stephan},
title = {Two cases of therapy-refractory chilblain lupus erythematosus successfully treated with deucravacitinib},
journal = {Lupus},
year = {2026},
doi = {10.1177/09612033261473986}
}
EUVIMED